Remove pharma
article thumbnail

As AI proliferates in pharma, regulators look to catch up in clinical trials

PharmaVoice

The FDA’s newly launched Center for Clinical Trial Innovation potentially opens the door for more efficient and expanded AI use, but leaves pharmas wanting more guidance.

287
287
article thumbnail

In his State of the Union, Biden takes clear aim at ‘Big Pharma’

STAT

But President Biden blasted the pharmaceutical industry with its unflattering moniker, “Big Pharma,” not once, but three times Thursday night, only the second time ever that sobriquet has been used in such a setting, after Biden’s address last year. Read the rest…

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Unlocking growth: How GenAI can help pharma companies convert new clients

PharmaVoice

Projections indicate that the global GenAI market in pharma will soar to USD 2258.1 GenAI is profoundly reshaping various facets of the pharmaceutical industry. million by 2032.

264
264
article thumbnail

STAT+: AstraZeneca picks up rare-disease focused Amolyt Pharma in $1 billion deal

STAT

LONDON —   AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial. The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.  

310
310
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

New pharma CEOs in the hot seat

STAT

A road test for fresh pharma CEOs A lot can change in five years — including the leadership of the three major pharmaceutical companies that will be testifying before Sen. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.  Bernie Sanders’ HELP Committee today.

article thumbnail

STAT+: Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH

STAT

The drug, survodutide, is being developed by the privately held German firm Boehringer Ingelheim and the Danish biotech Zealand Pharma. Zealand’s share price has doubled over the past year over the potential of the drug, and on Monday morning, shares jumped another 25%.  

360
360